Description
Dosage and Administration
- Administration:
Dobuscan is administered intravenously by a qualified healthcare professional in a clinical setting. - Dosage:
The recommended dose is 0.1 mL/kg body weight. The specific volume administered depends on the patient’s weight and the imaging requirements. - Preparation:
No special patient preparation is required. However, maintaining adequate hydration before and after administration is advisable to support renal function.
Side Effects
- Headache:
Mild to moderate pain in the head region. - Nausea:
Feelings of sickness or discomfort in the stomach. - Dizziness:
Light headedness or fainting sensations. - Allergic Reactions:
Hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. - Nephrogenic Systemic Fibrosis (NSF):
Symptoms include skin thickening, joint stiffness, and muscle weakness.
Seek immediate medical attention if any serious side effects occur.
Precautions
- Kidney Function:
Gadobutrol may increase the risk of acute kidney injury, especially in patients with pre-existing kidney problems. Assess renal function prior to administration. - Allergies:
Inform your doctor of any known allergies to gadolinium-based contrast agents or other medications. - Pregnancy and Breastfeeding:
Consult your healthcare provider before use, as the effects on fetal development and nursing infants are not fully established. - Gadolinium Retention:
Trace amounts of gadolinium may remain in the body, including the brain, for an extended period. The clinical significance of this retention is currently unknown.
